# PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD

Study · id `cardio:ct-nct04543812` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04543812](<https://clinicaltrials.gov/study/NCT04543812>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04543812

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 141 participants.

## Technical summary

Registry record NCT04543812. Randomized; quadruple masking; primary purpose treatment. Start 2020-10-14 (actual); primary completion 2022-10-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 141 participants (enrolled count; ClinicalTrials.gov record NCT04543812, source copy `cardio:ctgov-nct04543812-2025-06-29`, retrieved 2026-10-26)
- Started: 2020-10-14 (actual) (ClinicalTrials.gov record NCT04543812, source copy `cardio:ctgov-nct04543812-2025-06-29`, retrieved 2026-10-26)
- Primary completion: 2022-10-28 (actual) (ClinicalTrials.gov record NCT04543812, source copy `cardio:ctgov-nct04543812-2025-06-29`, retrieved 2026-10-26)
- Completion: 2022-12-16 (actual) (ClinicalTrials.gov record NCT04543812, source copy `cardio:ctgov-nct04543812-2025-06-29`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT04543812, source copy `cardio:ctgov-nct04543812-2025-06-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04543812-2025-06-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
- Condition: Anemia of Chronic Kidney Disease
- Intervention (Drug): Ferric citrate
- Intervention (Drug): Placebo
- Lead sponsor: Panion & BF Biotech Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Panion & BF Biotech Inc. (`cardio:org-panion-bf-biotech-inc`)

## Provenance

Content hash: ced958c13362f04046f9d278ddd65532eb9d91dd9a63d26ba05fea4965a5daf3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
